Global RNAi for Therapeutic Market Size, Manufacturers, Supply Chain, Sales Channel and Clients, 2022-2028
Table of Contents1 Study Coverage
1.1 RNAi for Therapeutic Product Introduction
1.2 Market by Type
1.2.1 Global RNAi for Therapeutic Market Size Growth Rate by Type (2017 VS 2021 VS 2028)
1.2.2 siRNA
1.2.3 miRNA
1.2.4 shRNA
1.3 Market by Application
1.3.1 Global RNAi for Therapeutic Market Size Growth Rate by Application (2017 VS 2021 VS 2028)
1.3.2 Cancer
1.3.3 Cardiovascular
1.3.4 HBV
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global RNAi for Therapeutic Market Size Estimates and Forecasts
2.2 RNAi for Therapeutic Market Size by Region: 2022 Versus 2028
2.2.1 Global RNAi for Therapeutic Revenue by Region: 2017-2022
2.2.2 Global RNAi for Therapeutic Revenue Forecast by Region (2023-2028)
2.2.3 Global RNAi for Therapeutic Revenue Market Share by Region (2017-2028)
3 Global RNAi for Therapeutic by Company
3.1 Global RNAi for Therapeutic Revenue by Company (2017-2022)
3.2 Global RNAi for Therapeutic Revenue Share by Company (2017-2022)
3.3 Competitive Landscape
3.3.1 Key RNAi for Therapeutic Companies around the World: Ranking by Revenue
3.3.2 Global RNAi for Therapeutic Market Concentration Ratio (CR5 and HHI) & (2017-2022)
3.3.3 Global RNAi for Therapeutic Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.4 Global RNAi for Therapeutic Companies Headquarters & Product Type
3.4.1 RNAi for Therapeutic Companies Headquarters
3.4.2 Global RNAi for Therapeutic Companies Product & Service
3.4.3 Date of International Companies Enter into RNAi for Therapeutic Market
3.5 Global RNAi for Therapeutic Mergers & Acquisitions, Expansion Plans
4 Company Profiles
4.1 Alnylam Pharmaceuticals
4.1.1 Alnylam Pharmaceuticals Corporation Information
4.1.2 Alnylam Pharmaceuticals Description, Business Overview
4.1.3 Alnylam Pharmaceuticals RNAi for Therapeutic Products Offered
4.1.4 Alnylam Pharmaceuticals RNAi for Therapeutic Revenue and Gross Margin (2017-2022)
4.1.5 Alnylam Pharmaceuticals RNAi for Therapeutic Revenue by Product in 2021
4.1.6 Alnylam Pharmaceuticals RNAi for Therapeutic Revenue by Application in 2021
4.1.7 Alnylam Pharmaceuticals RNAi for Therapeutic Revenue by Geographic Area in 2021
4.1.8 Alnylam Pharmaceuticals Recent Developments
4.2 Arbutus Biopharma (Tekmira)
4.2.1 Arbutus Biopharma (Tekmira) Corporation Information
4.2.2 Arbutus Biopharma (Tekmira) Description, Business Overview
4.2.3 Arbutus Biopharma (Tekmira) RNAi for Therapeutic Products Offered
4.2.4 Arbutus Biopharma (Tekmira) RNAi for Therapeutic Revenue and Gross Margin (2017-2022)
4.2.5 Arbutus Biopharma (Tekmira) RNAi for Therapeutic Revenue by Product in 2021
4.2.6 Arbutus Biopharma (Tekmira) RNAi for Therapeutic Revenue by Application in 2021
4.2.7 Arbutus Biopharma (Tekmira) RNAi for Therapeutic Revenue by Geographic Area in 2021
4.2.8 Arbutus Biopharma (Tekmira) Recent Developments
4.3 Arrowhead
4.3.1 Arrowhead Corporation Information
4.3.2 Arrowhead Description, Business Overview
4.3.3 Arrowhead RNAi for Therapeutic Products Offered
4.3.4 Arrowhead RNAi for Therapeutic Revenue and Gross Margin (2017-2022)
4.3.5 Arrowhead RNAi for Therapeutic Revenue by Product in 2021
4.3.6 Arrowhead RNAi for Therapeutic Revenue by Application in 2021
4.3.7 Arrowhead RNAi for Therapeutic Revenue by Geographic Area in 2021
4.3.8 Arrowhead Recent Developments
4.4 Dicerna Pharmaceuticals
4.4.1 Dicerna Pharmaceuticals Corporation Information
4.4.2 Dicerna Pharmaceuticals Description, Business Overview
4.4.3 Dicerna Pharmaceuticals RNAi for Therapeutic Products Offered
4.4.4 Dicerna Pharmaceuticals RNAi for Therapeutic Revenue and Gross Margin (2017-2022)
4.4.5 Dicerna Pharmaceuticals RNAi for Therapeutic Revenue by Product in 2021
4.4.6 Dicerna Pharmaceuticals RNAi for Therapeutic Revenue by Application in 2021
4.4.7 Dicerna Pharmaceuticals RNAi for Therapeutic Revenue by Geographic Area in 2021
4.4.8 Dicerna Pharmaceuticals Recent Developments
4.5 Mirna Therapeutics
4.5.1 Mirna Therapeutics Corporation Information
4.5.2 Mirna Therapeutics Description, Business Overview
4.5.3 Mirna Therapeutics RNAi for Therapeutic Products Offered
4.5.4 Mirna Therapeutics RNAi for Therapeutic Revenue and Gross Margin (2017-2022)
4.5.5 Mirna Therapeutics RNAi for Therapeutic Revenue by Product in 2021
4.5.6 Mirna Therapeutics RNAi for Therapeutic Revenue by Application in 2021
4.5.7 Mirna Therapeutics RNAi for Therapeutic Revenue by Geographic Area in 2021
4.5.8 Mirna Therapeutics Recent Developments
4.6 Quark Pharmaceuticals
4.6.1 Quark Pharmaceuticals Corporation Information
4.6.2 Quark Pharmaceuticals Description, Business Overview
4.6.3 Quark Pharmaceuticals RNAi for Therapeutic Products Offered
4.6.4 Quark Pharmaceuticals RNAi for Therapeutic Revenue and Gross Margin (2017-2022)
4.6.5 Quark Pharmaceuticals RNAi for Therapeutic Revenue by Product in 2021
4.6.6 Quark Pharmaceuticals RNAi for Therapeutic Revenue by Application in 2021
4.6.7 Quark Pharmaceuticals RNAi for Therapeutic Revenue by Geographic Area in 2021
4.6.8 Quark Pharmaceuticals Recent Development
4.7 RXi Pharmaceuticals
4.7.1 RXi Pharmaceuticals Corporation Information
4.7.2 RXi Pharmaceuticals Description, Business Overview
4.7.3 RXi Pharmaceuticals RNAi for Therapeutic Products Offered
4.7.4 RXi Pharmaceuticals RNAi for Therapeutic Revenue and Gross Margin (2017-2022)
4.7.5 RXi Pharmaceuticals RNAi for Therapeutic Revenue by Product in 2021
4.7.6 RXi Pharmaceuticals RNAi for Therapeutic Revenue by Application in 2021
4.7.7 RXi Pharmaceuticals RNAi for Therapeutic Revenue by Geographic Area in 2021
4.7.8 RXi Pharmaceuticals Recent Development
4.8 Silence Therapeutics
4.8.1 Silence Therapeutics Corporation Information
4.8.2 Silence Therapeutics Description, Business Overview
4.8.3 Silence Therapeutics RNAi for Therapeutic Products Offered
4.8.4 Silence Therapeutics RNAi for Therapeutic Revenue and Gross Margin (2017-2022)
4.8.5 Silence Therapeutics RNAi for Therapeutic Revenue by Product in 2021
4.8.6 Silence Therapeutics RNAi for Therapeutic Revenue by Application in 2021
4.8.7 Silence Therapeutics RNAi for Therapeutic Revenue by Geographic Area in 2021
4.8.8 Silence Therapeutics Recent Development
4.9 Benitec Biopharma
4.9.1 Benitec Biopharma Corporation Information
4.9.2 Benitec Biopharma Description, Business Overview
4.9.3 Benitec Biopharma RNAi for Therapeutic Products Offered
4.9.4 Benitec Biopharma RNAi for Therapeutic Revenue and Gross Margin (2017-2022)
4.9.5 Benitec Biopharma RNAi for Therapeutic Revenue by Product in 2021
4.9.6 Benitec Biopharma RNAi for Therapeutic Revenue by Application in 2021
4.9.7 Benitec Biopharma RNAi for Therapeutic Revenue by Geographic Area in 2021
4.9.8 Benitec Biopharma Recent Development
4.10 miRagen Therapeutics
4.10.1 miRagen Therapeutics Corporation Information
4.10.2 miRagen Therapeutics Description, Business Overview
4.10.3 miRagen Therapeutics RNAi for Therapeutic Products Offered
4.10.4 miRagen Therapeutics RNAi for Therapeutic Revenue and Gross Margin (2017-2022)
4.10.5 miRagen Therapeutics RNAi for Therapeutic Revenue by Product in 2021
4.10.6 miRagen Therapeutics RNAi for Therapeutic Revenue by Application in 2021
4.10.7 miRagen Therapeutics RNAi for Therapeutic Revenue by Geographic Area in 2021
4.10.8 miRagen Therapeutics Recent Development
4.11 Sylentis
4.11.1 Sylentis Corporation Information
4.11.2 Sylentis Description, Business Overview
4.11.3 Sylentis RNAi for Therapeutic Products Offered
4.11.4 Sylentis RNAi for Therapeutic Revenue and Gross Margin (2017-2022)
4.11.5 Sylentis RNAi for Therapeutic Revenue by Product in 2021
4.11.6 Sylentis RNAi for Therapeutic Revenue by Application in 2021
4.11.7 Sylentis RNAi for Therapeutic Revenue by Geographic Area in 2021
4.11.8 Sylentis Recent Development
4.12 Gradalis
4.12.1 Gradalis Corporation Information
4.12.2 Gradalis Description, Business Overview
4.12.3 Gradalis RNAi for Therapeutic Products Offered
4.12.4 Gradalis RNAi for Therapeutic Revenue and Gross Margin (2017-2022)
4.12.5 Gradalis RNAi for Therapeutic Revenue by Product in 2021
4.12.6 Gradalis RNAi for Therapeutic Revenue by Application in 2021
4.12.7 Gradalis RNAi for Therapeutic Revenue by Geographic Area in 2021
4.12.8 Gradalis Recent Development
4.13 Sirnaomics
4.13.1 Sirnaomics Corporation Information
4.13.2 Sirnaomics Description, Business Overview
4.13.3 Sirnaomics RNAi for Therapeutic Products Offered
4.13.4 Sirnaomics RNAi for Therapeutic Revenue and Gross Margin (2017-2022)
4.13.5 Sirnaomics RNAi for Therapeutic Revenue by Product in 2021
4.13.6 Sirnaomics RNAi for Therapeutic Revenue by Application in 2021
4.13.7 Sirnaomics RNAi for Therapeutic Revenue by Geographic Area in 2021
4.13.8 Sirnaomics Recent Development
4.14 Silenseed
4.14.1 Silenseed Corporation Information
4.14.2 Silenseed Description, Business Overview
4.14.3 Silenseed RNAi for Therapeutic Products Offered
4.14.4 Silenseed RNAi for Therapeutic Revenue and Gross Margin (2017-2022)
4.14.5 Silenseed RNAi for Therapeutic Revenue by Product in 2021
4.14.6 Silenseed RNAi for Therapeutic Revenue by Application in 2021
4.14.7 Silenseed RNAi for Therapeutic Revenue by Geographic Area in 2021
4.14.8 Silenseed Recent Development
5 Breakdown Data by Type
5.1 Global RNAi for Therapeutic Revenue by Type (2017-2022)
5.2 Global RNAi for Therapeutic Revenue Forecast by Type (2023-2028)
5.3 RNAi for Therapeutic Revenue Marke Share by Type (2017-2028)
6 Breakdown Data by Application
6.1 Global RNAi for Therapeutic Revenue by Application (2017-2022)
6.2 Global RNAi for Therapeutic Revenue Forecast by Application (2023-2028)
6.3 RNAi for Therapeutic Revenue Market Share by Application (2017-2028)
7 North America
7.1 North America RNAi for Therapeutic Market Size YoY Growth 2017-2028
7.2 North America RNAi for Therapeutic Market Facts & Figures by Country (2017-2028)
7.3 North America RNAi for Therapeutic Revenue by Type (2017-2022)
7.4 North America RNAi for Therapeutic Revenue by Application (2017-2022)
8 Asia-Pacific
8.1 Asia-Pacific RNAi for Therapeutic Market Size YoY Growth 2017-2028
8.2 Asia-Pacific RNAi for Therapeutic Market Facts & Figures by Region (2017-2028)
8.3 Asia-Pacific RNAi for Therapeutic Revenue by Type (2017-2022)
8.4 Asia-Pacific RNAi for Therapeutic Revenue by Application (2017-2022)
9 Europe
9.1 Europe RNAi for Therapeutic Market Size YoY Growth 2017-2028
9.2 Europe RNAi for Therapeutic Market Facts & Figures by Country (2017-2028)
9.3 Europe RNAi for Therapeutic Revenue by Type (2017-2022)
9.4 Europe RNAi for Therapeutic Revenue by Application (2017-2022)
10 Latin America
10.1 Latin America RNAi for Therapeutic Market Size YoY Growth 2017-2028
10.2 Latin America RNAi for Therapeutic Market Facts & Figures by Country (2017-2028)
10.3 Latin America RNAi for Therapeutic Revenue by Type (2017-2022)
10.4 Latin America RNAi for Therapeutic Revenue by Application (2017-2022)
11 Middle East and Africa
11.1 Middle East and Africa RNAi for Therapeutic Market Size YoY Growth 2017-2028
11.2 Middle East and Africa RNAi for Therapeutic Market Facts & Figures by Country (2017-2028)
11.3 Middle East and Africa RNAi for Therapeutic Revenue by Type (2017-2022)
11.4 Middle East and Africa RNAi for Therapeutic Revenue by Application (2017-2022)
12 Supply Chain and Sales Channel Analysis
12.1 RNAi for Therapeutic Supply Chain Analysis
12.2 RNAi for Therapeutic Key Raw Materials and Upstream Suppliers
12.3 RNAi for Therapeutic Clients Analysis
12.4 RNAi for Therapeutic Sales Channel and Sales Model Analysis
12.4.1 RNAi for Therapeutic Distribution Channel Analysis: Indirect Sales VS Direct Sales
12.4.2 RNAi for Therapeutic Distribution Channel Analysis: Online Sales VS Offline Sales
12.4.3 RNAi for Therapeutic Distributors
13 Market Dynamics
13.1 RNAi for Therapeutic Industry Trends
13.2 RNAi for Therapeutic Market Drivers
13.3 RNAi for Therapeutic Market Challenges
13.4 RNAi for Therapeutic Market Restraints
14 Research Findings and Conclusion
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer
List of TablesTable 1. Global RNAi for Therapeutic Market Size Growth Rate by Type (US$ Million): 2017 VS 2021 VS 2028
Table 2. Major Companies of siRNA
Table 3. Major Companies of miRNA
Table 4. Major Companies of shRNA
Table 5. Global RNAi for Therapeutic Market Size Growth by Application (US$ Million): 2017 VS 2021 VS 2028
Table 6. Global RNAi for Therapeutic Market Size by Region (US$ Million): 2022 VS 2028
Table 7. Global RNAi for Therapeutic Revenue by Region (2017-2022) & (US$ Million)
Table 8. Global RNAi for Therapeutic Revenue Forecast by Region (2023-2028) & (US$ Million)
Table 9. RNAi for Therapeutic Revenue by Company (2017-2022) & (US$ Million)
Table 10. RNAi for Therapeutic Revenue Share by Company (2017-2022)
Table 11. Ranking of Global Top RNAi for Therapeutic Players by Revenue (US$ Million) in 2021
Table 12. Global RNAi for Therapeutic Companies Market Concentration Ratio (CR5 and HHI) & (2017-2022)
Table 13. Global RNAi for Therapeutic by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in RNAi for Therapeutic as of 2021)
Table 14. Global RNAi for Therapeutic Companies Headquarters
Table 15. Global RNAi for Therapeutic Companies Product & Service
Table 16. Date of International Companies Enter into RNAi for Therapeutic Market
Table 17. Global RNAi for Therapeutic Mergers & Acquisitions, Expansion Plans
Table 18. Alnylam Pharmaceuticals Corporation Information
Table 19. Alnylam Pharmaceuticals Description and Business Overview
Table 20. Alnylam Pharmaceuticals RNAi for Therapeutic Revenue (US$ Million) and Gross Margin (2017-2022)
Table 21. Alnylam Pharmaceuticals RNAi for Therapeutic Product
Table 22. Alnylam Pharmaceuticals RNAi for Therapeutic Revenue Proportion of RNAi for Therapeutic by Product in 2021
Table 23. Alnylam Pharmaceuticals RNAi for Therapeutic Revenue Proportion of RNAi for Therapeutic by Application in 2021
Table 24. Alnylam Pharmaceuticals RNAi for Therapeutic Revenue Proportion of RNAi for Therapeutic by Geographic Area in 2021
Table 25. Alnylam Pharmaceuticals Recent Development
Table 26. Arbutus Biopharma (Tekmira) Corporation Information
Table 27. Arbutus Biopharma (Tekmira) Description and Business Overview
Table 28. Arbutus Biopharma (Tekmira) RNAi for Therapeutic Revenue (US$ Million) and Gross Margin (2017-2022)
Table 29. Arbutus Biopharma (Tekmira) RNAi for Therapeutic Product
Table 30. Arbutus Biopharma (Tekmira) RNAi for Therapeutic Revenue Proportion of RNAi for Therapeutic by Product in 2021
Table 31. Arbutus Biopharma (Tekmira) RNAi for Therapeutic Revenue Proportion of RNAi for Therapeutic by Application in 2021
Table 32. Arbutus Biopharma (Tekmira) RNAi for Therapeutic Revenue Proportion of RNAi for Therapeutic by Geographic Area in 2021
Table 33. Arbutus Biopharma (Tekmira) Recent Development
Table 34. Arrowhead Corporation Information
Table 35. Arrowhead Description and Business Overview
Table 36. Arrowhead RNAi for Therapeutic Revenue (US$ Million) and Gross Margin (2017-2022)
Table 37. Arrowhead RNAi for Therapeutic Product
Table 38. Arrowhead RNAi for Therapeutic Revenue Proportion of RNAi for Therapeutic by Product in 2021
Table 39. Arrowhead RNAi for Therapeutic Revenue Proportion of RNAi for Therapeutic by Application in 2021
Table 40. Arrowhead RNAi for Therapeutic Revenue Proportion of RNAi for Therapeutic by Geographic Area in 2021
Table 41. Arrowhead Recent Development
Table 42. Dicerna Pharmaceuticals Corporation Information
Table 43. Dicerna Pharmaceuticals Description and Business Overview
Table 44. Dicerna Pharmaceuticals RNAi for Therapeutic Revenue (US$ Million) and Gross Margin (2017-2022)
Table 45. Dicerna Pharmaceuticals RNAi for Therapeutic Product
Table 46. Dicerna Pharmaceuticals RNAi for Therapeutic Revenue Proportion of RNAi for Therapeutic by Product in 2021
Table 47. Dicerna Pharmaceuticals RNAi for Therapeutic Revenue Proportion of RNAi for Therapeutic by Application in 2021
Table 48. Dicerna Pharmaceuticals RNAi for Therapeutic Revenue Proportion of RNAi for Therapeutic by Geographic Area in 2021
Table 49. Dicerna Pharmaceuticals Recent Development
Table 50. Mirna Therapeutics Corporation Information
Table 51. Mirna Therapeutics Description and Business Overview
Table 52. Mirna Therapeutics RNAi for Therapeutic Revenue (US$ Million) and Gross Margin (2017-2022)
Table 53. Mirna Therapeutics RNAi for Therapeutic Product
Table 54. Mirna Therapeutics RNAi for Therapeutic Revenue Proportion of RNAi for Therapeutic by Product in 2021
Table 55. Mirna Therapeutics RNAi for Therapeutic Revenue Proportion of RNAi for Therapeutic by Application in 2021
Table 56. Mirna Therapeutics RNAi for Therapeutic Revenue Proportion of RNAi for Therapeutic by Geographic Area in 2021
Table 57. Mirna Therapeutics Recent Development
Table 58. Quark Pharmaceuticals Corporation Information
Table 59. Quark Pharmaceuticals Description and Business Overview
Table 60. Quark Pharmaceuticals RNAi for Therapeutic Revenue (US$ Million) and Gross Margin (2017-2022)
Table 61. Quark Pharmaceuticals RNAi for Therapeutic Product
Table 62. Quark Pharmaceuticals RNAi for Therapeutic Revenue Proportion of RNAi for Therapeutic by Product in 2021
Table 63. Quark Pharmaceuticals RNAi for Therapeutic Revenue Proportion of RNAi for Therapeutic by Application in 2021
Table 64. Quark Pharmaceuticals RNAi for Therapeutic Revenue Proportion of RNAi for Therapeutic by Geographic Area in 2021
Table 65. RXi Pharmaceuticals Corporation Information
Table 66. RXi Pharmaceuticals Description and Business Overview
Table 67. RXi Pharmaceuticals RNAi for Therapeutic Revenue (US$ Million) and Gross Margin (2017-2022)
Table 68. RXi Pharmaceuticals RNAi for Therapeutic Product
Table 69. RXi Pharmaceuticals RNAi for Therapeutic Revenue Proportion of RNAi for Therapeutic by Product in 2021
Table 70. RXi Pharmaceuticals RNAi for Therapeutic Revenue Proportion of RNAi for Therapeutic by Application in 2021
Table 71. RXi Pharmaceuticals RNAi for Therapeutic Revenue Proportion of RNAi for Therapeutic by Geographic Area in 2021
Table 72. Silence Therapeutics Corporation Information
Table 73. Silence Therapeutics Description and Business Overview
Table 74. Silence Therapeutics RNAi for Therapeutic Revenue (US$ Million) and Gross Margin (2017-2022)
Table 75. Silence Therapeutics RNAi for Therapeutic Product
Table 76. Silence Therapeutics RNAi for Therapeutic Revenue Proportion of RNAi for Therapeutic by Product in 2021
Table 77. Silence Therapeutics RNAi for Therapeutic Revenue Proportion of RNAi for Therapeutic by Application in 2021
Table 78. Silence Therapeutics RNAi for Therapeutic Revenue Proportion of RNAi for Therapeutic by Geographic Area in 2021
Table 79. Benitec Biopharma Corporation Information
Table 80. Benitec Biopharma Description and Business Overview
Table 81. Benitec Biopharma RNAi for Therapeutic Revenue (US$ Million) and Gross Margin (2017-2022)
Table 82. Benitec Biopharma RNAi for Therapeutic Product
Table 83. Benitec Biopharma RNAi for Therapeutic Revenue Proportion of RNAi for Therapeutic by Product in 2021
Table 84. Benitec Biopharma RNAi for Therapeutic Revenue Proportion of RNAi for Therapeutic by Application in 2021
Table 85. Benitec Biopharma RNAi for Therapeutic Revenue Proportion of RNAi for Therapeutic by Geographic Area in 2021
Table 86. miRagen Therapeutics Corporation Information
Table 87. miRagen Therapeutics Description and Business Overview
Table 88. miRagen Therapeutics RNAi for Therapeutic Revenue (US$ Million) and Gross Margin (2017-2022)
Table 89. miRagen Therapeutics RNAi for Therapeutic Product
Table 90. miRagen Therapeutics RNAi for Therapeutic Revenue Proportion of RNAi for Therapeutic by Product in 2021
Table 91. miRagen Therapeutics RNAi for Therapeutic Revenue Proportion of RNAi for Therapeutic by Application in 2021
Table 92. miRagen Therapeutics RNAi for Therapeutic Revenue Proportion of RNAi for Therapeutic by Geographic Area in 2021
Table 93. Sylentis Corporation Information
Table 94. Sylentis Description and Business Overview
Table 95. Sylentis RNAi for Therapeutic Revenue (US$ Million) and Gross Margin (2017-2022)
Table 96. Sylentis RNAi for Therapeutic Product
Table 97. Sylentis RNAi for Therapeutic Revenue Proportion of RNAi for Therapeutic by Product in 2021
Table 98. Sylentis RNAi for Therapeutic Revenue Proportion of RNAi for Therapeutic by Application in 2021
Table 99. Sylentis RNAi for Therapeutic Revenue Proportion of RNAi for Therapeutic by Geographic Area in 2021
Table 100. Gradalis Corporation Information
Table 101. Gradalis Description and Business Overview
Table 102. Gradalis RNAi for Therapeutic Revenue (US$ Million) and Gross Margin (2017-2022)
Table 103. Gradalis RNAi for Therapeutic Product
Table 104. Gradalis RNAi for Therapeutic Revenue Proportion of RNAi for Therapeutic by Product in 2021
Table 105. Gradalis RNAi for Therapeutic Revenue Proportion of RNAi for Therapeutic by Application in 2021
Table 106. Gradalis RNAi for Therapeutic Revenue Proportion of RNAi for Therapeutic by Geographic Area in 2021
Table 107. Sirnaomics Corporation Information
Table 108. Sirnaomics Description and Business Overview
Table 109. Sirnaomics RNAi for Therapeutic Revenue (US$ Million) and Gross Margin (2017-2022)
Table 110. Sirnaomics RNAi for Therapeutic Product
Table 111. Sirnaomics RNAi for Therapeutic Revenue Proportion of RNAi for Therapeutic by Product in 2021
Table 112. Sirnaomics RNAi for Therapeutic Revenue Proportion of RNAi for Therapeutic by Application in 2021
Table 113. Sirnaomics RNAi for Therapeutic Revenue Proportion of RNAi for Therapeutic by Geographic Area in 2021
Table 114. Silenseed Corporation Information
Table 115. Silenseed Description and Business Overview
Table 116. Silenseed RNAi for Therapeutic Revenue (US$ Million) and Gross Margin (2017-2022)
Table 117. Silenseed RNAi for Therapeutic Product
Table 118. Silenseed RNAi for Therapeutic Revenue Proportion of RNAi for Therapeutic by Product in 2021
Table 119. Silenseed RNAi for Therapeutic Revenue Proportion of RNAi for Therapeutic by Application in 2021
Table 120. Silenseed RNAi for Therapeutic Revenue Proportion of RNAi for Therapeutic by Geographic Area in 2021
Table 121. Global RNAi for Therapeutic Revenue by Type (2017-2022) & (US$ Million)
Table 122. Global RNAi for Therapeutic Revenue by Application (2017-2022) & (US$ Million)
Table 123. Global RNAi for Therapeutic Revenue Forecast by Application (2023-2028) & (US$ Million)
Table 124. North America RNAi for Therapeutic Revenue by Country (2017-2022) & (US$ Million)
Table 125. North America RNAi for Therapeutic Revenue by Country (2023-2028) & (US$ Million)
Table 126. North America RNAi for Therapeutic Revenue by Type (2017-2022) & (US$ Million)
Table 127. North America RNAi for Therapeutic Revenue by Application (2017-2022) & (US$ Million)
Table 128. Asia-Pacific RNAi for Therapeutic Revenue by Region (2017-2028) & (US$ Million)
Table 129. Asia-Pacific RNAi for Therapeutic Revenue by Region (2023-2028) & (US$ Million)
Table 130. Asia-Pacific RNAi for Therapeutic Revenue by Type (2017-2022) & (US$ Million)
Table 131. Asia-Pacific RNAi for Therapeutic Revenue by Application (2017-2022) & (US$ Million)
Table 132. Europe RNAi for Therapeutic Revenue by Country (2017-2022) & (US$ Million)
Table 133. Europe RNAi for Therapeutic Revenue by Country (2023-2028) & (US$ Million)
Table 134. Europe RNAi for Therapeutic Revenue by Type (2017-2022) & (US$ Million)
Table 135. Europe RNAi for Therapeutic Revenue by Application (2017-2022) & (US$ Million)
Table 136. Latin America RNAi for Therapeutic Revenue by Country (2017-2022) & (US$ Million)
Table 137. Latin America RNAi for Therapeutic Revenue by Country (2023-2028) & (US$ Million)
Table 138. Latin America RNAi for Therapeutic Revenue by Type (2017-2022) & (US$ Million)
Table 139. Latin America RNAi for Therapeutic Revenue by Application (2017-2022) & (US$ Million)
Table 140. Middle East and Africa RNAi for Therapeutic Revenue by Country (2017-2022) & (US$ Million)
Table 141. Middle East and Africa RNAi for Therapeutic Revenue by Country (2023-2028) & (US$ Million)
Table 142. Middle East and Africa RNAi for Therapeutic Revenue by Type (2017-2022) & (US$ Million)
Table 143. Middle East and Africa RNAi for Therapeutic Revenue by Application (2017-2022) & (US$ Million)
Table 144. RNAi for Therapeutic Key Raw Materials, Industry Status and Trend
Table 145. RNAi for Therapeutic Key Raw Materials and Upstream Suppliers
Table 146. RNAi for Therapeutic Clients Status and Trend
Table 147. RNAi for Therapeutic Typical Clients
Table 148. RNAi for Therapeutic Distributors
Table 149. RNAi for Therapeutic Market Trends
Table 150. RNAi for Therapeutic Market Drivers
Table 151. RNAi for Therapeutic Market Challenges
Table 152. RNAi for Therapeutic Market Restraints
Table 153. Research Programs/Design for This Report
Table 154. Key Data Information from Secondary Sources
Table 155. Key Data Information from Primary Sources
List of FiguresFigure 1. RNAi for Therapeutic Product Picture
Figure 2. Global RNAi for Therapeutic Revenue Market Share by Type in 2021 & 2028
Figure 3. siRNA Product Picture
Figure 4. miRNA Product Picture
Figure 5. shRNA Product Picture
Figure 6. Global RNAi for Therapeutic Revenue Market Share by Application in 2021 & 2028
Figure 7. Cancer
Figure 8. Cardiovascular
Figure 9. HBV
Figure 10. Others
Figure 11. RNAi for Therapeutic Report Years Considered
Figure 12. Global RNAi for Therapeutic Revenue, (US$ Million), 2017 VS 2021 VS 2028
Figure 13. Global RNAi for Therapeutic Market Size 2017-2028 (US$ Million)
Figure 14. Global RNAi for Therapeutic Market Size Market Share by Region: 2022 Versus 2028
Figure 15. Global RNAi for Therapeutic Revenue Market Share by Region (2017-2028)
Figure 16. RNAi for Therapeutic Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2017 VS 2021
Figure 17. Global RNAi for Therapeutic Revenue Market Share Forecast by Type (2017-2028)
Figure 18. Global RNAi for Therapeutic Revenue Market Share Forecast by Application (2017-2028)
Figure 19. North America RNAi for Therapeutic Revenue 2017-2028 (US$ Million)
Figure 20. North America RNAi for Therapeutic Revenue Market Share by Type (2017-2022)
Figure 21. North America RNAi for Therapeutic Revenue Market Share by Application (2017-2022)
Figure 22. Asia-Pacific RNAi for Therapeutic Revenue 2017-2028 (US$ Million)
Figure 23. Asia-Pacific RNAi for Therapeutic Revenue Market Share by Region (2017-2028)
Figure 24. Asia-Pacific RNAi for Therapeutic Revenue Market Share by Type (2017-2022)
Figure 25. Asia-Pacific RNAi for Therapeutic Revenue Market Share by Application (2017-2022)
Figure 26. Europe RNAi for Therapeutic Revenue Growth Rate 2017-2028 (US$ Million)
Figure 27. Europe RNAi for Therapeutic Revenue Market Share by Country (2017-2028)
Figure 28. Europe RNAi for Therapeutic Revenue Market Share by Type (2017-2022)
Figure 29. Europe RNAi for Therapeutic Revenue Market Share by Application (2017-2022)
Figure 30. Latin America RNAi for Therapeutic Revenue Growth Rate 2017-2028 (US$ Million)
Figure 31. Latin America RNAi for Therapeutic Revenue Market Share by Country (2017-2022)
Figure 32. Latin America RNAi for Therapeutic Revenue Market Share by Type (2017-2022)
Figure 33. Latin America RNAi for Therapeutic Revenue Market Share by Application (2017-2022)
Figure 34. Middle East and Africa RNAi for Therapeutic Revenue Growth Rate 2017-2028 (US$ Million)
Figure 35. Middle East and Africa RNAi for Therapeutic Revenue Market Share by Country (2017-2028)
Figure 36. Middle East and Africa RNAi for Therapeutic Revenue Market Share by Type (2017-2022)
Figure 37. Middle East and Africa RNAi for Therapeutic Revenue Market Share by Application (2017-2022)
Figure 38. RNAi for Therapeutic Supply Chain (Upstream and Downstream Market)
Figure 39. Global Production Market Share of RNAi for Therapeutic Raw Materials by Region in 2021
Figure 40. RNAi for Therapeutic Distribution Channels
Figure 41. Global RNAi for Therapeutic Percentage 2017-2028: Indirect Sales VS Direct Sales
Figure 42. Global RNAi for Therapeutic Percentage 2017-2028: Online Sales VS Offline Sales
Figure 43. Bottom-up and Top-down Approaches for This Report
Figure 44. Data Triangulation
Figure 45. Key Executives Interviewed